Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
-
Thukukile Zuma Resigns from ANC Johannesburg Leadership Amid Disciplinary Dispute
-
Russia Orders 100,000 Kometa Modules to Counter Ukrainian Electronic Warfare
-
CM Mohan Yadav Meets Bohra Spiritual Leader to Discuss Simhastha 2028 and Development
-
Mahayuti-backed Rajesh Patil Elected Chairman of Gokul Dairy Amidst Political Deadlock
-
Eli Crane Defeats Jonathan Nez in Tight Arizona Congressional Race
-
David Walliams Identified as Celebrity in Sexual Misconduct Allegations After Legal Bid
-
Sherilyn Smith Encourages Women to Embrace Scars as Symbols of Resilience
-
Korea's Severe Asthma Patients Blocked from Biologics by Restrictive Reimbursement Rules
-
Belgium Signs Contract for 20 Rheinmetall Skyranger Air Defence Systems
-
Shanghai Science and Technology Museum Signs Pacts With London and Ottawa Institutions at CIIE
-
NextBoat Inc. to Announce Third Quarter 2026 Financial and Operating Results on Monday, November 16, 2026
-
Shooting Victim Lawyer in Philadelphia David P. Thiruselvam Explains When Property Owners and Businesses Can Face Civil Claims After a Shooting
-
Retired Army Officer Earns Two Degrees While Navigating Family Health Challenges
-
Remergify Opens Waitlist for AI Allowance, a Plain-English Way to Let AI Assistants Shop Within Limits You Set
-
An Investigational Drug to Tackle Measles Outbreaks
-
Ondas Receives Purchase Order for Next-Generation Tactical Attack Drones, Aims to Leverage Planned ARAN Defense Acquisition to Manufacture Thousands of Systems
-
First Breach Plans to Integrate Onboard AI Computing into CQS and LRS Drone Platforms
-
Stabilis Solutions Announces Three-Year Take-Or-Pay LNG Supply Agreement with Existing Aerospace Customer
-
ACCESS Newswire Reports Third Quarter 2026 Results
-
T4 Robotics Appoints Paul Hughes as Co-CEO and Announces Expansion into Unmanned Maritime Systems
-
ClearSign Receives Order for "M1" Series Burner from Tulsa Heaters Midstream (THM)
-
Kalm with Kava and Pū'iwa Farms Hawai'i Bring Fresh Frozen Hawaiian Kava to Market
-
Innovative Menopause Medicine from JASTLabs Advances Patent Protection Internationally
-
SMX Advances Development of its Scientific Intelligence, an AI-Powered Platform Intended to Create a Comprehensive Codex for Chemical Agents, Additives and Supplements
-
Jerash Holdings Reports Fiscal 2027 Second Quarter Financial Results
-
Four Nines Gold Intersects 67 Metres at 1.78 g/t Gold, Reinforing Emerging Gold Corridor at Hayden Hill
-
Peraso to Showcase DUNE 60 GHz Wireless Platform at Africa Tech Festival 2026
-
Your Patients Are Asking AI About You. AimwellBio Lets Every Physician See the Answer, Free.
-
ByNext Joins the Bilt Neighborhood: Reaching More Customers by Integrating Its Technology with Bilt Neighborhood OS
-
ATWEC Technologies, Inc. (OTCID:ATWT) Reports Third Quarter 2026 Revenue of $12.46 Million, Up 37% Year-over-Year
-
Cardiff Lexington To Report Third Quarter 2026 Financial Results and Host Conference Call on Monday, November 16, 2026
-
Horizon Aircraft Completes Preliminary Design Review of Cavorite X7 Hybrid eVTOL
-
Securitas Healthcare Introduces a New Era of RTLS Built for the Future of Healthcare Operations
-
BioTech Breakthrough Acknowledges Champions Oncology Innovation with the "Contract Research and Development Innovation Award"
-
Allstar Health Brands Confirms MLS NEXT Expansion Bid to Anchor a Permanent Training Structure and a Professional Pathway
-
SNZweig Forms AEC Industry Advisory Council
-
Critical Elements' 10,000-Meter Summer Drill Program at Rose West Continues to Deliver Positive Results
-
New Gold IRA Investing Guide Explains How to Buy Gold in an IRA for American Consumers
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 10
-
Fulcrum Metals PLC Announces Fulcrum to Increase Shareholding in Loyalist
-
Spectrocell Strengthens Product Discovery and Customer Engagement with Bioz Badges
-
3D Induced Polarization Survey Identifies a Large Drill Target at East Goldfield
-
Apex Extends Trinity Zone in West Step-out Drilling With 2.52% REO Over 223.3 m and 2.49% REO Over 123.3 m at Rift
-
KIFFIK Biomedical Recognized as Top Biomarker Access Technology 2026 by Life Sciences Review
-
Zomedica Announces "Third Friday at Four" Webinar on November 20, 2026: The People Behind Zomedica - Seven Guiding Principles in Action, and Q3 Financial Results
-
Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
-
Geek+ Unveils 24/7 Warehouse Autonomy Plan to Advance Self-Optimizing, Around-the-Clock Operation
-
Gamma Resources Announces Planned Radon Flux Baseline Survey at Mesa Arc Uranium Project in New Mexico, Provides Update on Project Timelines
-
China Explores a New Pathway for Medical AI: Bridging R&D Innovation and Clinical Adoption
-
Odyssey Behavioral Healthcare Launches Virtual Intensive Outpatient Mental Health Treatment for Adults
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
FORT LAUDERDALE, FL / ACCESS Newswire / April 1, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 annual report on Form 10-K on Tuesday, April 1, 2025. The following are highlights of the report:
Revenue in 2024 grew to $34.9 million, a 45% increase over 2023 revenue of $24.1 million.
Completed an underwritten public offering of approximately $10 million in gross proceeds for expansion of sales operations.
Launched 13 new generic prescription drugs, 4 under cross-licensing agreements and 9 under distribution agreements.
Received regulatory approval from Health Canada for marketing of the oncology drug NIOPEG®, a biosimilar of NEULASTA®.
Announced publication of groundbreaking research results in the Journal of Medicinal Chemistry (J. Med. Chem. 2024, 67, 13681−13702) demonstrating the superior efficacy of Sunshine Biopharma's new Coronavirus PLpro inhibitor. The study showcases a PLpro inhibitor with sub-micromolar potency and robust in vivo efficacy in a mouse model of SARS-CoV-2 infection. This peer-reviewed research marks an important milestone in Sunshine Biopharma's ongoing efforts to develop proprietary therapies in critical disease areas.
Announced completion of mouse model studies providing proof-of-concept for the Company's K1.1 mRNA Lipid Nanoparticle as a novel therapeutic agent for human hepatocellular carcinoma. Human hepatocellular carcinoma is the third leading cause of cancer-related deaths worldwide and the most common type of primary liver cancer in adults.
"We are pleased with our accomplishments in 2024, as we remain committed to reaching profitability in the near future," said Dr. Steve Slilaty, CEO of the Company. "Looking ahead, we are excited about the opportunities for growth in 2025 and beyond, as we continue to advance our proprietary drug development program to deliver more life-saving medicines to the market."
The following are key elements of the Income Statement contained in the Company's 2024 report:
2024 | 2023 | |||
Revenue | $ | 34,874,283 | $ | 24,092,787 |
Gross Profit | $ | 10,669,794 | $ | 8,339,171 |
General & Administrative Expenses | $ | 16,481,915 | $ | 13,124,470 |
Net Loss | $ | 5,134,116 | $ | 4,506,044 |
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and 13 additional drugs scheduled to be launched in the remainder of 2025. Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
All registered trademarks are the property of their respective owners.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For more information, please contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire
M.Thompson--AMWN
